🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

The future of precision cancer therapy might be to try everything. A news feature @nature “Researchers are blasting patients’ cancer cells with dozens of drugs in the hope of finding the right treatment” - Is this the future ? OncoAlert nature.com/articles/d4158…

📢 2 cabozantinib trials of orphan cancers (adrenocortical carcinoma and metastatic phaeochromocytoma/paraganglioma(MPPG)) were published in The Lancet Oncology 1️⃣Cabozantinib seems a promising option for advanced adrenocortical carcinoma! ⚡️A phase-2 investigator-initiated

Immune checkpoint blockers in pts with solid organ transplant and solid tumors. Potential treatm for some pts but limited activity for pts with SOT and 🫁cancer.1/3 have organ rejection within 2mo after treatment initiation.Thanks all authors! OncoAlert authors.elsevier.com/sd/article/S20…

Online first: Results from DESTINY-PanTumor01: #Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations: an international, phase 2 study thelancet.com/journals/lanon…

Don´t miss this Review summarizing the different antibody-based approaches for targeting cancer cells including #CheckpointInhibitors, bispecific antibodies and #AntibodyDrugConjugates, as well as strategies that improve efficacy and reduce toxicities. go.nature.com/3wWetGE

Recommendations for the use of NGS for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group ✅️ESMO expands tumour NGS recommendations to include BC, GIST, thyroid cancer, and CUP OncoAlert #precisionmedicine annalsofoncology.org/article/S0923-…

Exciting news! The Phase 3 KEYNOTE-522 trial met its OS endpoint in high-risk early-stage TNBC patients. This confirms the therapy's extraordinary potential in saving lives. #bcsm #TNBC

Node-negative subanalysis of NATALEE (n=613). Mostly includes patients with T2 disease (75%), virtually all with G2-3 disease. Consistent benefit in iDFS (93.2% vs 90.6%, HR 0.72), DDFS and DRFS with adjuvant ribociclib. Safety also consistent with ITT. #ASCO24 #bcsm

Do patients with ER-low (1-10%) tumors benefit from adjuvant ET⁉️ At #ASCO24 an analysis of >10,000 ER-low tumors shows that ET omission was associated with ⬇️ overall survival, suggesting that adjuvant ET should be recommended to these patients as standard of care OncoAlert

Encouraging results from the phase 2 trial of camrelizumab + apatinib in previously treated, advanced #adrenocortical carcinoma by #ZhigongWei ORR 52% DCR 95% PFS 12.6mo OS 20.9mo + acceptable toxicity Interesting thoughts regarding biomarkers of response: peripheral CD4/8?

#ASCO24 DESTINY-Breast07: T-DXd and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC (phase 1b/2) First-line!!!! ORR T-DXD➡️76% T-DXd +P➡️84% 1y PFS➡️80.8% and 89.4% Presented by Prof FabriceAndre OncoAlert

The CAPItello-290 Phase III trial for capivasertib + paclitaxel mTNBC did not meet the dual primary endpoints of improvement in OS vs. pacli + placebo in either the overall population or in pts with PIK3CA, AKT1 or PTEN alterations OncoAlert astrazeneca.com/media-centre/p…

📌 Hormone receptor-positive early breast cancer in young women: A comprehensive review - Cancer Treatment Reviews 👉🏻 current evidence in hormone receptor-positive YWBC including specific risk factors, clinicopathologic and genomic features, and available evidence on response to

Presented at #ESMO24: Cabozantinib, as compared with placebo, doubled progression-free survival in patients with extrapancreatic neuroendocrine tumors and tripled it in patients with pancreatic neuroendocrine tumors. Full CABINET trial results: nej.md/3AYuEoI

The #OncoAlertTopTweet Day One #SABCS24 Post by OncoAlert 🚨Faculty Stephanie Graff, MD, FACP, FASCO 🇺🇸 Cannnabis can have drug interactions💊 that either decrease the efficacy of #BreastCancer treatment or, by slowing metabolism, ultimately prolong side effects. Matteo Lambertini, MD PhD 🇮🇹 Erika Hamilton, MD 🇺🇸

“It is impressive that the combination [of imlunestrant and abemaciclib] seems to tower above the rest” —Harold J. Burstein, MD, PhD, FASCO, sharing his self-proclaimed dreaded cross trial comparison (students, biostatisticians: *avert your eyes*) #SABCS24 OncoAlert

The new #Halgorithm for treating HR+/HER2- metastatic breast cancer Harold J. Burstein, MD, PhD, FASCO SABCS Dana-Farber’s Breast Oncology Center #bcsm #SABCS24

Association between risk reducing surgeries and survival in young BRCA carriers with #BreastCancer Accumulating crucial evidence presented by amazing Prof Matteo Lambertini #SABCS24 Matteo Lambertini, MD PhD OncoAlert #OncoAlert

In his review on chemotherapy use in older women with breast cancer, Hans Wildiers UZ Leuven concludes “Every Oncologist should become a geriatric oncologist.” #SGBCC2025 SIOG

🚨 Wow! #ASCO25 ASCO was absolutely massive! 10 NEJM papers published simultaneously 👉 all practice-changing studies ! 🔬✨🧵 See below for these studies 👇@oncoalert